<p>Rucaparib is a ground-breaking PARP inhibitor used in treating advanced ovarian, fallopian tube, and peritoneal cancers, particularly in patients with BRCA mutations. Its ability to block DNA repair in cancer cells makes it an effective targeted therapy, offering hope to patients with limited options.<br />Leading Rucaparib exporters play a pivotal role in making this life-saving drug accessible globally. By adhering to stringent quality standards and ensuring timely delivery, these exporters contribute to improved patient outcomes. Their commitment to innovation and affordability helps bridge the gap in cancer care, supporting healthcare providers and enhancing global cancer treatment efforts.</p>